Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ironwood/AstraZeneca Approved to Market IBS-C Treatment in China

publication date: Jan 15, 2019

Ironwood Pharma reported that China approved its treatment for irritable bowel syndrome with constipation (IBS-C). Ironwood, which is partnering the China marketing of the drug with AstraZeneca, expects to launch Linzess® (linaclotide) in China during the second half of 2019. Linaclotide is a guanylate cyclase-C (GC-C) receptor agonist that is approved in the US and more than 30 other countries. Ironwood estimates there are 14 million patients suffering from IBS-C in China. More details....

Stock Symbols: (NSDQ: IRWD) (NYSE: AZN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.